NeuroD1 can induce the transformation of pancreatic cancer cells from a malignant phenotype to neurons with a benign phenotype; thus, screening for drugs that regulate and induce NeuroD1 expression may facilitate the treatment of pancreatic cancer. Here, NEUROD1 is linked to familial pancreatic carcinoma.